Oruka Therapeutics, Inc. ORKA Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value?
- Oruka Therapeutics, Inc. (ORKA) reported share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value of $160.99M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value changed year-over-year?
- Oruka Therapeutics, Inc.'s share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value increased by 3322.3% year-over-year, from $4.7M to $160.99M.